Bottom line
Is FTXH a good fund? The bottom line
FTXH is an actively managed health care sector ETF from First Trust.
Its expense ratio is 0.6% — about $60 a year on every $10,000 invested, cheaper than 77% of health care sector funds we track.
It returned +24.0% over one year, +6.5% a year over five years (as of Dec 31, 2025, per its prospectus).
With $36.2 million in net assets and 51 holdings, its largest position is Eli Lilly & Company (7.8%) and the top 10 make up 53.1% of the portfolio.
The closest lower-cost alternative we found is XLV (0.08%, 50% top-holdings overlap).
What stands out
- Low cost: cheaper than 77% of health care sector peers
- 5-year return beat 77% of category peers
What to watch
- Concentrated: top 10 holdings are 53.1% of assets
- Small fund ($36.2 million) — small funds are likelier to close
Updated Nov 19, 2026
What FTXH invests in
The First Trust Nasdaq Pharmaceuticals ETF (the Fund ) seeks investment results that correspond generally to the price and yield (before the Funds fees and expenses) of an equity index called the Nasdaq US Smart Pharmaceuticals TM Index (the Index ).
Under normal market conditions, the Fund will invest at least 80% of its net assets (plus any investment borrowings) in the securities that comprise the Index. The Fund, using an indexing investment approach, attempts to replicate, before fees and expenses, the performance of the Index. The Index is owned and is developed, maintained and sponsored by Nasdaq, Inc. (the Index Provider ). The Index Provider may, from time to time, exercise reasonable discretion as it deems appropriate in order to ensure Index integrity. According to the Index Provider, the Index is designed to provide exposure to the 30 to 50 top factor-ranked securities from U.S. pharmaceutical and biotechnology companies. The Indexs initial selection universe consists of the component securities of the Nasdaq US Benchmark TM Index that have been classified as comprising the pharmaceuticals and biotechnology subsectors…
From the fund's prospectus (filed Jul 29, 2026).
FTXH performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| FTXH | +24.0% | +6.5% | — |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What FTXH costs
On a $10,000 investment, FTXH's 0.6% expense ratio costs about $60 a year. The median health care sector fund charges 0.96%.
FTXH top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Company LLY | 7.77% |
| 2 | Abbvie Inc ABBV | 7.39% |
| 3 | Merck & Company Inc MRK | 7.07% |
| 4 | Johnson & Johnson JNJ | 6.96% |
| 5 | Bristol-myers Squibb Company BMY | 6.29% |
| 6 | Biogen Inc BIIB | 3.84% |
| 7 | Viatris Inc VTRS | 3.62% |
| 8 | Cardinal Health Inc CAH | 3.53% |
| 9 | Vertex Pharmaceuticals Inc VRTX | 3.41% |
| 10 | Amgen Inc AMGN | 3.18% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 53.1% of the fund. See all top 25 holdings and asset mix →